Robert B. Rothermel buys more than 6000 shares in the APMP

Adamis Pharmaceuticals Corp (NASDAQ:ADMP) Director Robert B. Rothermel, in a transaction of business’s stock that occurred on Fridayn May 24th, acquired 6,500 shares. The shares were bought at the $1.58 price which resulted in having a total of $10,270.00 value. After the acquisition’s completion, the shares that the director owns is of 133,500 of the stock of the company overall. The overall shares had a value of $210,930. In the legal filing, the transaction was disclosed with the Securities & Exchange Commission. This can easily be accessed via the website of SEC.

NASDAQ ADMP traded down $0.02 during trading on Tuesday, hitting $1.47. 211,200 shares of the company traded hands, compared to its average volume of 383,336. Adamis Pharmaceuticals Corp has a 12 month low of $1.33 and a 12 month high of $5.10. The company has a debt-to-equity ratio of 0.03, a current ratio of 1.53 and a quick ratio of 1.24. The firm has a market cap of $69.04 million, a P/E ratio of -1.47 and a beta of 1.53.

The earnings results were posted by the Adamis Pharmaceuticals (NASDAQ:ADMP) on Thursday, May 9th. Earnings per share were posted by the specialty pharmaceutical for the quarter which was about $0.19. It didn’t have the Thomson Reuters’ which was around $0.15. Moreover, there was a negative net margin of 239.53% to the Adamis Pharmaceuticals. The negative net margin resulted in negative equity of 94.94%. For the quarter, the company had reserved around $4.91 million. For the ongoing year, some of the analysts have analyzed that the Adamis Pharmaceuticals Corp will have the equity of –0.49 EPS.

Several brokerages gave a report on ADMP. Around $10.00 price has been placed as an objective by Maxim Group on the Adamis Pharmaceuticals and a buy rating was reported on Tuesday, 19th of March. Around $4.00 price was set as an object by the Raymond James on the Adamis Pharmaceuticals, on Friday, 10th of May. Some of the analysis reports show that the stock has been rated by two analysts which has hold rating while the other three have already given the buy rating to the company. As for the current analysis, the stock has the buy rating and the price is around of $5.25.